Your browser doesn't support javascript.
loading
Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase.
Zigmond, Ehud; Ben Ya'acov, Ami; Lee, Hyunbeom; Lichtenstein, Yoav; Shalev, Zvi; Smith, Yoav; Zolotarov, Lidya; Ziv, Ehud; Kalman, Rony; Le, Hoang V; Lu, Hejun; Silverman, Richard B; Ilan, Yaron.
Afiliação
  • Zigmond E; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Ben Ya'acov A; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Lee H; Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University , Evanston, Illinois 60208, United States.
  • Lichtenstein Y; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Shalev Z; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Smith Y; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Zolotarov L; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Ziv E; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Kalman R; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
  • Le HV; Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University , Evanston, Illinois 60208, United States.
  • Lu H; Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University , Evanston, Illinois 60208, United States.
  • Silverman RB; Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, and Center for Molecular Innovation and Drug Discovery, Northwestern University , Evanston, Illinois 60208, United States.
  • Ilan Y; Liver Unit, Genomic Data Analysis Unit, and Diabetes Unit, Faculty of Medicine, Hebrew University-Hadassah Medical Center , Jerusalem 91120, Israel.
ACS Med Chem Lett ; 6(8): 840-4, 2015 Aug 13.
Article em En | MEDLINE | ID: mdl-26288681
ABSTRACT
Hepatocellular carcinoma is the second leading cause of cancer death worldwide. DNA microarray analysis identified the ornithine aminotransferase (OAT) gene as a prominent gene overexpressed in hepatocellular carcinoma (HCC) from Psammomys obesus. In vitro studies demonstrated inactivation of OAT by gabaculine (1), a neurotoxic natural product, which suppressed in vitro proliferation of two HCC cell lines. Alpha-fetoprotein (AFP) secretion, a biomarker for HCC, was suppressed by gabaculine in both cell lines, but not significantly. Because of the active site similarity between GABA aminotransferase (GABA-AT) and OAT, a library of 24 GABA-AT inhibitors was screened to identify a more selective inhibitor of OAT. (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidene)cyclopentane-1-carboxylic acid (2) was found to be an inactivator of OAT that only weakly inhibits GABA-AT, l-aspartate aminotransferase, and l-alanine aminotransferase. In vitro administration of 2 significantly suppressed AFP secretion in both Hep3B and HepG2 HCC cells; in vivo, 2 significantly suppressed AFP serum levels and tumor growth in HCC-harboring mice, even at 0.1 mg/kg. Overexpression of the OAT gene in HCC and the ability to block the growth of HCC by OAT inhibitors support the role of OAT as a potential therapeutic target to inhibit HCC growth. This is the first demonstration of suppression of HCC by an OAT inactivator.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article